U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Voriconazole Tablets, Powder for Oral Suspension, Injection
  1. Development Resources

Voriconazole Tablets, Powder for Oral Suspension, Injection

Recognized Interpretive Criteria

  Minimum Inhibitory
Concentrations
(mcg/mL)
Broth Microdilution
at 24 Hours
Disk Diffusion
(zone diameters in mm)

Disk Diffusion at 24 Hours
Pathogen S I R S I R
Candida albicans M27M44S standard is recognized M27M44S standard is recognized
Candida krusei M27M44S standard is recognized M27M44S standard is recognized
Candida parapsilosis M27M44S standard is recognized M27M44S standard is recognized
Candida tropicalis M27M44S standard is recognized M27M44S standard is recognized

S = Susceptible; I = Intermediate; R = Resistant

For C. glabrata and voriconazole, current data are insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome.

Back to Top